Ching-Tai Huang

Title: Innovations in Cancer Treatment by Ching-Tai Huang

Introduction

Ching-Tai Huang is a prominent inventor based in Taipei, Taiwan. She has made significant contributions to the field of cancer treatment through her innovative research and patented methods. With a total of four patents, her work focuses on enhancing T cell immune responses to combat cancer effectively.

Latest Patents

Huang's latest patents include groundbreaking methods for increasing T cell immune response in cancer treatment. One of her notable inventions is a method that combines anti-cancer antibodies with inhibitory antibodies to CD223, which helps overcome immune suppression in cancer patients. The inhibitory antibodies can be generated in an animal by injecting fragments of CD223. These antibodies may take the form of monoclonal antibodies, single-chain antibodies, or humanized antibodies. Another significant patent involves methods for treatment that comprise an antibody binding to the CD223 protein, where anti-CD223 antibodies are utilized to counteract immune suppression in cancer patients. Similar to her previous patent, these antibodies can also be generated through the injection of fragments of CD223.

Career Highlights

Throughout her career, Huang has worked with esteemed institutions such as St. Jude Children's Research Hospital and The Johns Hopkins University. Her research has been pivotal in advancing the understanding and treatment of cancer, particularly in enhancing the immune response.

Collaborations

Huang has collaborated with notable colleagues in her field, including Drew M. Pardoll and Jonathan David Powell. These collaborations have further enriched her research and contributed to the development of innovative cancer therapies.

Conclusion

Ching-Tai Huang's contributions to cancer treatment through her patented methods demonstrate her commitment to advancing medical science. Her innovative approaches have the potential to significantly improve the lives of cancer patients.